AlphaYouTBPH: Weiss Asset Management LP; WEISS ANDREW M; WAM GP LLC discloses securities transactions
By AlphaYouPublished Form 4
Weiss Asset Management LP; WEISS ANDREW M; WAM GP LLC
Reporting filer
Weiss Asset Management LP; WEISS ANDREW M; WAM GP LLC reported Other (see filing) in Theravance Biopharma, Inc.: 7457060 units of Ordinary Share $0.00001 Par Value, dated 2026-09-23. The full Form 4 contains 1 transaction entry.
- Disclosed
- Sep 28, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Ordinary Share $0.00001 Par Value | Weiss Asset Management LP; WEISS ANDREW M; WAM GP LLC | 2026-09-23 | J | Other (see filing) | 7457060 | 17 | 0 | 5 days | Filed terms
|
Ordinary Share $0.00001 Par Value
- Owner
- Weiss Asset Management LP; WEISS ANDREW M; WAM GP LLC
- Date
- 2026-09-23
- Code
- J
- Action
- Other (see filing)
- Quantity
- 7457060
- Price
- 17
- Following holdings
- 0
- Reporting delay
- 5 days
- Filed terms and references
Filed terms
- security Title: Ordinary Share $0.00001 Par Value
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: J
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 7457060
- id: F2
- transaction Price Per Share: 17
- id: F3
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 0
- direct Or Indirect Ownership: I
- nature Of Ownership: See Footnote 2
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Weiss Asset Management LP: Other reporting owner.
- WEISS ANDREW M: Other reporting owner.
- WAM GP LLC: Other reporting owner.
- F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each Ordinary Share $0.00001 Par Value of the Issuer held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
- F2: Shares reported herein represent shares beneficially owned by two private investment funds for which Weiss Asset Management LP serves as investment manager. WAM GP LLC is the general partner of Weiss Asset Management LP and Andrew Weiss is the Manager of WAM GP LLC. All of Weiss Asset Management LP, WAM GP LLC, and Andrew Weiss disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest therein.
- F3: Represents the cash portion of the consideration paid to shareholders upon the closing of the Merger.
Original sources
Prepared automatically from public filing data. Report a correction.